PDCD1 and neoplasm: Since SOX10 has been shown to negatively correlate with PD-L1 expression on tumor cells, targeting SOX10 may not only enhance tumor cell ICD, but may also improve responses to anti-PD-1/-PD-L1 therapies by its direct effects on PD-L1 expression [64].